SCHEDULE: TPG Funds Divest All Allogene Therapeutics Shares

TPG Funds have sold all their shares in Allogene Therapeutics, Inc. on September 28, 2026, marking the end of their significant beneficial ownership.

Summary

• TPG GP A, LLC, James G. Coulter, and Jon Winkelried (collectively, the 'Reporting Persons') have filed an amendment to their Schedule 13D regarding Allogene Therapeutics, Inc.
• The filing reports the sale of an aggregate of 18,716,306 shares of Common Stock by the TPG Funds on September 28, 2026, at a price of $1.55 per share.
• This sale was conducted pursuant to Rule 144 under the Securities Act of 1933.
• As a result of this offering, the Reporting Persons no longer beneficially own any shares of Common Stock and have ceased to be beneficial owners of more than five percent of the shares.
• The filing details the complex structure of TPG entities involved in the beneficial ownership and reporting.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing, primarily due to the complete divestment of shares and the cessation of significant beneficial ownership, indicating a shift in investment strategy or conclusion of their involvement.

Positives

• The sale was executed at a specific price ($1.55 per share), providing clarity on the transaction value.
• The transaction was conducted under Rule 144, indicating compliance with securities regulations for the sale of restricted stock.

Negatives

• The Reporting Persons have completely divested their holdings in Allogene Therapeutics, Inc.
• The Reporting Persons no longer beneficially own any shares of Common Stock, indicating a complete exit from their investment.
• The Reporting Persons are no longer beneficial owners of more than five percent of the shares, signifying a loss of significant stake.

Risks

• The sale of a large block of shares could potentially impact the stock price if not absorbed by the market, although this is a past event.
• The reason for the complete divestment is not explicitly stated, which could imply a lack of confidence in the company's future prospects from the perspective of a major investor.

Future Outlook

The filing does not contain any forward-looking statements or guidance from the Reporting Persons regarding future investments or actions related to Allogene Therapeutics, Inc., as they have fully divested their holdings.

Management Comments

• Reporting Persons disclaim beneficial ownership of the shares of Common Stock held by the TPG Funds except to the extent of their pecuniary interest therein.

Industry Context

StockSavvy.ai notes that the divestment by a significant investor like TPG can signal a change in their investment thesis or a realization of gains/losses. For Allogene Therapeutics, this marks the exit of a notable investment firm, which could be interpreted by the market in various ways depending on the broader context of the company's performance and TPG's overall investment strategy.

Stakeholder Impact

• Shareholders may experience short-term price volatility due to the sale of a large block of shares, though the sale occurred on a specific date.
• The market may interpret TPG's exit as a signal, potentially influencing investor sentiment towards Allogene Therapeutics.

Next Steps

• The Reporting Persons have completed their divestment of Allogene Therapeutics, Inc. shares.
• The Reporting Persons will no longer be required to file Schedule 13D amendments for this issuer unless they reacquire a significant stake.

Key Dates

Keywords

Allogene Therapeutics, TPG, Schedule 13D, Share Sale, Divestment, Rule 144, Beneficial Ownership